At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 18 Dec 2003 No development reported - Preclinical for Pain in Canada (unspecified route)
- 15 Jun 2001 Preclinical development for Pain in Canada (Unknown route)